Trial site
Hattiesburg Clinic
Hattiesburg, Mississippi 39401, United StatesNot linked to an institution yet
- 15running trials
- 8closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 25 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Recruiting8 trials
- Completed7 trials
- Active, not recruiting6 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Regeneron Pharmaceuticals4 trials
- Janssen Research & Development, LLC3 trials
- Alector Inc.2 trials
- Bristol-Myers Squibb2 trials
- Cognito Therapeutics, Inc.2 trials
- and 8 more
Running trials
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· Phase 2· Bristol-Myers Squibb· Source
Contact: John Hrom, Site 0180
Recruiting
Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component
NCT07682597· Timothy Mullett· Source
Contact: Joseph Alexander
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· Phase 3· Bristol-Myers Squibb· Source
Contact: Ronald Schwartz, Site 2629
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543· Phase 4· Takeda· Source
Contact: John Hrom (principal investigator)
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258· Phase 2· Eisai Inc.· Source
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Enrolling by invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031· Cognito Therapeutics, Inc.· Source
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015· Phase 2/3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· Phase 2/3· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· Phase 3· Eisai Inc.· Source
Active, not recruiting
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
NCT02951598· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error